公开(公告)号：US20220348559A1

公开(公告)日：2022-11-03

申请号：US17198238

申请日：2021-03-10

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Craig STIVALA ,  Huifen CHEN ,  Guiling ZHAO

IPC: C07D403/12 ,  C07D413/12 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D495/04 ,  C07D491/04 ,  C07D491/10 ,  C07D413/14 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052 ,  C07D519/00

Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1, L, n, the A ring, the B ring, and the C ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.

公开(公告)号：US20210340151A1

公开(公告)日：2021-11-04

申请号：US17371001

申请日：2021-07-08

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D487/04

Abstract: Some embodiments of the invention provide compounds having the general formula I: wherein R1, R2, R3a and R3b are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20210139504A1

公开(公告)日：2021-05-13

申请号：US17147449

申请日：2021-01-12

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D498/04 ,  C07D487/04 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04

Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20240336625A1

公开(公告)日：2024-10-10

申请号：US18580607

申请日：2022-07-15

Applicant: Genentech, Inc.

Inventor： Kwong Wah LAI ,  Christian NILEWSKI ,  Richard M. PASTOR ,  Craig STIVALA

IPC: C07D498/04 ,  A61K31/424

CPC classification number: C07D498/04 ,  A61K31/424

Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.

公开(公告)号：US20210253596A1

公开(公告)日：2021-08-19

申请号：US17150349

申请日：2021-01-15

Applicant: Genentech, Inc.

Inventor： Christopher MCBRIDE ,  Lynnie Lin TRZOSS ,  Amogh BOLOOR ,  Nadezda V. SOKOLOVA ,  Richard M. PASTOR ,  Steven Thomas STABEN ,  Craig STIVALA ,  Matthew VOLGRAF ,  Sarah M. BRONNER

IPC: C07D498/04 ,  C07D231/18 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P31/16 ,  A61P31/14

Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

公开(公告)号：US20250115618A1

公开(公告)日：2025-04-10

申请号：US18988433

申请日：2024-12-19

Applicant: Genentech, Inc.

Inventor： Christopher MCBRIDE ,  Lynnie Lin TRZOSS ,  Amogh BOLOOR ,  Nadezda V. SOKOLOVA ,  Richard M. PASTOR ,  Steven Thomas STABEN ,  Craig STIVALA ,  Matthew VOLGRAF ,  Sarah M. BRONNER

IPC: C07D498/04 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61P31/18 ,  C07D231/18 ,  C07D471/04 ,  C07D487/04 ,  C07D513/04

Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.

公开(公告)号：US20240300974A1

公开(公告)日：2024-09-12

申请号：US18516014

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D498/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D498/04 ,  A61P25/16 ,  A61P25/28 ,  C07D235/12 ,  C07D471/04 ,  C07D487/04 ,  A61P1/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00

Abstract: The invention provides novel compounds having the general formula I:




wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20190100530A1

公开(公告)日：2019-04-04

申请号：US16034207

申请日：2018-07-12

Applicant: Genentech, Inc.

Inventor： Snahel PATEL ,  Gregory HAMILTON ,  Guiling ZHAO ,  Huifen CHEN ,  Blake DANIELS ,  Craig STIVALA

IPC: C07D498/04 ,  C07D487/04 ,  C07D471/04 ,  C07D235/12

Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

公开(公告)号：US20230159555A1

公开(公告)日：2023-05-25

申请号：US17814115

申请日：2022-07-21

Applicant: Genentech, Inc.

Inventor： Paul GIBBONS ,  Kwong Wah LAI ,  Christian NILEWSKI ,  Richard M. PASTOR ,  Steven Thomas STABEN ,  Craig STIVALA ,  Bing-Yan ZHU ,  Huifen CHEN

IPC: C07D498/04

CPC classification number: C07D498/04

Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B),




solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

公开(公告)号：US20210261568A1

公开(公告)日：2021-08-26

申请号：US17150380

申请日：2021-01-15

Applicant: Genentech, Inc.

Inventor： Jeffrey A. STAFFORD ,  James M. VEAL ,  Lynnie Lin TRZOSS ,  Christopher MCBRIDE ,  Richard M. PASTOR ,  Steven Thomas STABEN ,  Craig STIVALA ,  Matthew VOLGRAF

IPC: C07D498/04

Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.